OakChart

Standard BioTools Inc

LABHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 7:10 AM ET

0.6783+0.0133 (2.00%)
2026-11-11 14:39 CET
Market cap
262.54 USD m
Revenue, TTM
84.43 USD m
Net income, TTM
-69.20 USD m
Free cash flow, TTM
-65.65 USD m
EPS diluted, TTM
-0.18
P/E
-
Compare

Price

LAB against its 20, 50 and 200-day averages
2050200miss
0.600.801.001.2017.6M35.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LABclose 0.6820-day 0.6350-day 0.68200-day 0.880.68

60.6% under 1.72 on 22 Dec 2025. Last 15 sessions, 22.1% high to low

Profile

LAB
52-week range, 8% of the way up
0.591.72

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

Employees389
IPOFeb 10, 2011
Beta1.49
ATR, 14d0.04
Rel volume0.00
Short float0.57%
Insider own4.08%
Inst own73.89%

Snapshot

6 groups

Valuation

Index-
Market Cap267.79M
Enterprise Value-166.49M
Income-69.20M
Sales84.43M
Book/sh1.41
Cash/sh1.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees389
IPOFeb 10, 2011

Ratios

P/E-
Forward P/E-
PEG-
P/S3.17
P/B0.48
P/C0.58
P/FCF-
EV/EBITDA-
EV/Sales-1.97
Quick Ratio9.40
Current Ratio9.75
Debt/Eq0.05
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.18
EPS next Y-0.16
EPS next Q-0.02
EPS this Y33.33%
EPS next Y-60.00%
EPS next 5Y-
EPS past 3/5Y56.76% 23.22%
Sales past 3/5Y-4.49% -9.19%
EPS Y/Y TTM47.75%
Sales Y/Y TTM-34.46%
EPS Q/Q53.75%
Sales Q/Q-0.85%
EarningsAug 05 AMC
EPS/Sales Surpr.-446.88% -3.37%

Ownership

Insider Own4.08%
Insider Trans0.47%
Inst Own73.89%
Inst Trans-3.13%
ROA-6.34%
ROE-7.79%
ROIC-12.00%
Gross Margin50.82%
Oper. Margin-55.98%
Profit Margin-81.96%
SMA207.20%
SMA50-0.03%
SMA200-22.82%
Trades-

Technical

Shs Outstand394.67M
Shs Float378.68M
Short Float0.57%
Short Ratio1.82
Short Interest2.17M
52W High1.72 -60.56%
52W Low0.59 15.34%
Volatility6.54% 5.83%
ATR (14)0.04
RSI (14)56.16
Beta1.49
Rel Volume0.00
Avg Volume1.19M
Volume50

Performance

Perf Week10.11%
Perf Month2.94%
Perf Quarter-9.54%
Perf Half Y-32.84%
Perf YTD-47.01%
Perf Year-43.00%
Perf 3Y-68.89%
Perf 5Y-85.57%
Perf 10Y-89.32%
Recom3.00
Target Price1.35
Prev Close0.67
Price0.68
Change %2.00%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Aug 13, 2025DowngradeTTD CowenBuy → Hold$1.55+128.5%
Feb 27, 2025DowngradeKKeyBanc Capital MarketsOverweight → Sector Weight
Apr 16, 2024InitiatedTTD CowenBuy$3.50+416.0%
Apr 04, 2024InitiatedJJefferiesBuy$3.25+379.1%
Jul 12, 2023InitiatedKKeyBanc Capital MarketsOverweight$4+489.7%

Peers

Mkt cap
TickerCompanyMkt cap
QTRXQuanterix Corp152.41M
ALMRAlamar Biosciences Inc2.19B
CTKBCytek BioSciences Inc746.78M
QSIQuantum-Si Incorporated294.48M
TXG10x Genomics Inc8.47B
SEERSeer Inc83.61M
NAUTNautilus Biotechnology Inc303.14M
PACBPacific Biosciences of California Inc716.61M
MASS908 Devices Inc412.72M
BRKRBruker Corp9.66B

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Carey Thomas D.DirectorNov 05 '26Buy0.6375,00046,898419,456Nov 05 05:36 PM
Egholm MichaelPresident & CEOApr 06 '26Option Exercise0.00196,51306,790,596Apr 08 09:55 PM
Kim Hanjoon AlexChief Financial OfficerApr 06 '26Option Exercise0.0070,18302,800,702Apr 08 09:55 PM
Casdin Partners Master Fund, LDirectorDec 04 '25Buy1.45150,000217,02072,100,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorDec 02 '25Buy1.42125,000177,51271,875,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorDec 03 '25Buy1.4475,000108,03771,950,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorNov 25 '25Buy1.307,550,0009,838,40571,750,000Nov 26 04:58 PM
Casdin Partners Master Fund, LDirectorNov 24 '25Buy1.43150,000214,87564,200,000Nov 26 04:58 PM
Casdin Partners Master Fund, LDirectorNov 20 '25Buy1.30450,000586,26064,050,000Nov 20 07:45 PM
Casdin Partners Master Fund, LDirectorNov 19 '25Buy1.28350,000448,91063,600,000Nov 20 07:45 PM
Casdin Partners Master Fund, LDirectorNov 18 '25Buy1.23275,000339,40563,250,000Nov 20 07:45 PM
Casdin Partners Master Fund, LDirectorNov 13 '25Buy1.20450,000541,39562,500,000Nov 17 06:58 PM
Casdin Partners Master Fund, LDirectorNov 14 '25Buy1.24250,000309,80062,750,000Nov 17 06:58 PM
Casdin Partners Master Fund, LDirectorNov 17 '25Buy1.22225,000275,58062,975,000Nov 17 06:58 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IBBiShares Biotechnology ETFAUM: 11.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.32B
VHTVanguard Health Care ETFAUM: 21.40B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.65B
GNOMGlobal X Genomics & Biotechnology ETFAUM: 109.11M
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.68B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.92M
MSSMMorgan Stanley Pathway Small-Mid Cap Equity ETFAUM: 709.29M

News

latest 14 of 206
  • ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools' Microfluidics Business, Now Biomark Scientific (GlobeNewswire)
  • Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED (GlobeNewswire) -5.37%
  • Standard BioTools Provides Update on Sale of Mass Cytometry Business (GlobeNewswire)
  • Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Standard BioTools: Q2 Earnings Snapshot (Associated Press)
  • Loading…
  • Standard BioTools Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences (GlobeNewswire)
  • Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire) -7.43%
  • Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction (GlobeNewswire) -5.02%
  • Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Stealthy startup Treeline plans a reverse merger (BioPharma Dive) +10.33%
  • Standard BioTools and Treeline Biosciences Announce Merger Agreement (GlobeNewswire) -30.16%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-05-0.070-0.013-0.07020.1020.802
2026Q12026-05-05-0.040-0.047-0.11721.1517.803
2025Q42026-02-240.040-0.0540.05023.8018.503
2025Q32025-11-04-0.090-0.043-0.09119.5518.003
2025Q22025-08-11-0.050-0.067-0.08821.7639.823
2025Q12025-05-06-0.070-0.055-0.06940.8040.102
2024Q42025-02-26-0.090-0.057-0.09146.7243.033
2024Q32024-10-30-0.070-0.090-0.07344.9741.003
2024Q22024-07-31-0.120-0.083-0.12337.2148.253
2024Q12024-05-08-0.270-0.112-0.26645.5446.013
2023Q42024-02-28-0.250-0.240-0.24828.1924.901
2023Q32023-11-07-0.270-0.230-0.26525.3723.601
2023Q22023-08-08-0.220-0.210-0.21727.6724.201
2023Q12023-05-09-0.210--0.21325.12--
2022Q42023-02-14-0.260--0.26227.02--
2022Q32022-11-08-0.370--0.37325.65--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-1.490-1.480-1.488112.96111.3
2019FY-0.970-0.984-0.970117.24115.54
2020FY-0.740-0.554-0.736138.14144.27
2021FY-0.780-0.940-0.782130.58125
2022FY-2.430-1.000-2.42897.95124.4
2023FY-0.940-0.940-0.943106.34103
2024FY-0.520-0.357-0.523175.08171.2
2025FY-0.150-0.207-0.15085.3380.26
2026FY--0.100--82.50
2027FY--0.160--82.10
2028FY--0.140--85.70
2029FY--0.150--89.40

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-0610018.8018.8018.80
2026Q3S2026-08-0520018.4218.0318.80
2026Q3S2026-07-2020018.4218.0318.80
2026Q3S2026-06-0520218.4218.0318.80
2026Q3S2026-05-0820218.4018.0018.80
2026Q3S2026-05-0630219.0318.0020.30
2026Q3S2026-02-2530219.8319.6020.30
2026Q3S2026-01-1930020.1219.9020.30
2026Q3S2026-01-0731020.1219.9020.30
2026Q3S2025-11-1131020.1319.9020.30
2026Q3S2025-11-1031020.1319.9020.30
2026Q3S2025-11-0931020.1319.9020.30
2026Q3S2025-11-0831020.1319.9020.30
2026Q3S2025-11-0731020.1319.9020.30

Estimate history

EPS, annual-1.84-1.488-0.97-0.736-0.782-2.428-0.943-0.523-0.196-0.1768
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.073-0.091-0.069-0.088-0.0910.05-0.117-0.069-0.042
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual101.937112.964117.243138.144130.58197.948106.3491.00885.33184.43
Period201720182019202020212022202320242025TTM
Sales, quarterly44.96946.71840.79521.76219.55223.79521.14620.10419.385
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual38.78749.33869.95674.54376.91979.48280.232377.53386.381394.671
Period201720182019202020212022202320242025MRQ
Shares, quarterly372.261377.53379.087381.691383.614386.381390.141392.121394.671
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue84.4385.3391.01106.3497.95130.58138.14117.24112.96
Cost of Goods Sold Incl. D&A41.5242.7946.1255.8960.9061.2154.8252.9651.31
Gross Profit42.9142.5444.8850.4537.0569.3783.3364.2861.65
Selling, General and Administrative Excl. Other90.17135.85131.89113.49149.76136.83134.36115.67109.81
Research and Development13.9625.9928.8325.9535.0037.9436.4631.2030.03
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-47.26-93.31-87.01-63.04-112.70-67.46-51.04-51.40-48.16
Interest Expense-0.033.324.574.333.823.574.2813.89
Unusual Expense35.0316.9440.4813.5677.30-7.130.0012.46-
Net Income Before Taxes-73.03-96.70-90.40-74.20-192.93-63.66-54.10-66.70-61.42
Income Taxes-35.80-37.880.540.45-2.83-4.42-1.08-1.92-2.41
Consolidated Net Income-37.23-58.83-90.94-74.66-190.10-59.24-53.02-64.79-59.01
Net Income From Continuing Operations-37.23-58.83-90.94-74.66-190.10-59.24-53.02-64.79-59.01
Net Income-69.20-74.90-184.90-74.66-190.10-59.24-53.02-64.79-59.01
EPS (Recurring)-0.11-0.17-0.44-0.82-1.74-0.85-0.74-0.84-1.49
EPS (Basic, Before Extraordinaries)-0.18-0.20-0.52-0.94-2.43-0.78-0.74-0.97-1.49
EPS (Diluted)-0.18-0.20-0.52-0.94-2.43-0.78-0.74-0.97-1.49
EBITDA-42.09-86.32-81.70-47.86-97.68-51.39-33.09-35.59-31.66
Non-Operating Income (Expense)9.2713.5740.406.961.410.490.511.430.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.9020.3613.7510.3711.7611.7510.558.328.71
Price To Sales Ratio3.455.726.791.650.942.283.131.983.03
Gross Margin50.8249.8649.3247.4437.8353.1360.3254.8354.57
Operating Margin-55.98-109.34-95.60-59.28-115.07-51.66-36.94-43.84-42.64
Net Margin-81.96-87.77-203.17-70.21-194.08-45.36-38.38-55.26-52.24
Shares Outstanding394.67386.38377.5380.2379.4876.9274.5469.9649.34
Market Capitalization262.54262.54651.45176.8792.78299.82444.71242.09419.75

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue19.3920.1021.1523.8019.5521.7640.8046.72
Cost of Goods Sold Incl. D&A8.569.579.8413.5510.0711.1321.0526.65
Gross Profit10.8310.5411.3110.249.4810.6319.7420.07
Selling, General and Administrative Excl. Other18.9218.3620.7232.1632.9534.3350.0349.81
Research and Development2.081.982.127.796.366.2211.3313.19
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.09-7.83-9.42-21.92-23.47-23.70-30.29-29.74
Interest Expense---0.010.010.010.00-
Unusual Expense11.6817.563.082.729.472.002.683.08
Net Income Before Taxes-14.95-21.43-14.62-22.03-32.90-18.28-26.18-33.80
Income Taxes0.030.090.01-35.93-1.22-0.61-0.150.27
Consolidated Net Income-14.98-21.52-14.6313.90-31.68-17.67-26.03-34.07
Net Income From Continuing Operations-14.98-21.52-14.6313.90-31.68-17.67-26.03-34.07
Net Income-16.51-26.76-45.2219.28-34.69-33.46-26.03-34.07
EPS (Recurring)-0.02-0.04-0.110.06-0.07-0.08-0.06-0.09
EPS (Basic, Before Extraordinaries)-0.04-0.07-0.120.05-0.09-0.09-0.07-0.09
EPS (Diluted)-0.04-0.07-0.120.05-0.09-0.09-0.07-0.09
EBITDA-6.89-6.56-8.01-20.64-21.87-21.70-26.12-25.78
Non-Operating Income (Expense)4.823.95-2.122.620.057.426.79-0.98
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.943.203.953.815.954.247.125.90
Price To Sales Ratio3.453.804.144.653.862.962.413.76
Gross Margin55.8652.4053.4843.0348.5148.8448.3942.96
Operating Margin-41.75-38.94-44.53-92.14-120.02-108.90-74.26-63.65
Net Margin-85.15-133.10-213.8581.04-177.41-153.75-63.81-72.93
Shares Outstanding394.67392.12390.14386.38383.61381.69379.09377.53
Market Capitalization262.54321.16358.59492.24496.59455.79409.30651.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments187.57292.87114.89165.8028.4768.5459.7195.4063.14
Short Term Receivables13.4314.7419.6617.2818.3225.4218.9816.6515.05
Inventories19.9820.7420.5321.4720.8219.6913.8813.0015.09
Other Current Assets233.2847.523.134.264.454.013.522.051.53
Total Current Assets454.26375.88158.22208.8172.07117.6696.10127.1194.80
Net Property, Plant & Equipment46.0149.3454.8559.5365.1555.6512.928.8212.30
Total Investments and Advances28.132.090.801.001.001.001.000.000.00
Intangible Assets-140.25107.72119.43135.56148.79153.24165.92178.26
Deferred Tax Assets38.630.14-------
Other Assets0.72184.891.481.531.431.661.561.791.99
Total Assets567.75612.35323.07390.31275.21324.76264.81303.65287.35
Short Term Debt Incl. Current Port. of LT Debt5.494.8163.855.769.892.971.830.000.00
Accounts Payable5.415.059.247.9110.609.226.514.034.21
Income Tax Payable--1.23------
Other Current Liabilities97.4156.0435.0129.7629.0742.0624.4833.5529.26
Total Current Liabilities108.3165.89109.3343.4449.5754.2532.8237.5833.47
Long Term Debt25.3425.8934.3696.89101.7692.4058.14172.06195.24
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.811.080.841.054.338.7011.4913.7116.92
Other Liabilities9.0147.7615.3419.1424.9630.368.748.1810.79
Total Liabilities143.46140.62159.87160.52180.62185.71111.20231.53256.42
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00311.25311.250.000.000.000.000.00
Common Equity424.29471.72-148.05-81.4794.60139.05153.6172.1230.93
Total Shareholders Equity424.29471.72163.20229.7994.60139.05153.6172.1230.93
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity424.29471.72163.20229.7994.60139.05153.6172.1230.93
Total Liabilities & Stockholders Equity567.75612.35323.07390.31275.21324.76264.81303.65287.35
Book Value Per Share1.101.25-1.85-1.021.231.872.201.460.80
Tangible Book Value Per Share1.101.25-3.19-2.53-0.53-0.130.01-1.90-3.80
Full-Time Employees389818539523615627566535505
Price to Book Ratio0.471.33-1.33-1.483.193.221.585.905.82
Return on Assets-9.97-19.44-20.93-57.13-19.75-17.99-22.79-19.97-20.39
Return on Equity-13.13-28.65-37.99-117.21-50.71-36.23-57.41-114.53-143.84
Return on Invested Capital-16.66-27.91-37.79-58.19-30.17-22.91-30.60-24.17-26.76
Quick Ratio4.015.391.264.311.031.812.503.042.38
Current Ratio4.195.701.454.811.452.172.933.382.83

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income133.08-74.90-138.88-74.66-190.10-59.24-53.02-64.79-59.01
Depreciation5.176.983.8915.1815.0316.0717.9415.8016.57
Other Funds (Non Cash)-167.8538.5520.7314.40101.1819.0417.2527.0116.86
Funds from Operations8.76-29.36-114.26-45.07-73.89-24.13-17.83-21.97-25.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-73.02-44.98-29.201.79-15.48-19.932.41-13.24-2.48
Cash from Operating Activities-64.26-74.34-143.45-43.29-89.37-44.06-15.42-35.21-28.06
Capital Expenditures-1.39-8.30-8.36-2.83-3.83-13.26-12.72-2.53-0.37
Net Assets From Acquisitions0.000.00-1.390.000.000.00-5.150.00-
Sale of Fixed Assets and Businesses410.700.000.000.000.000.000.000.00-
Purchase or Sale of Investments-202.0240.7192.8823.07-84.300.0036.81-36.775.09
Purchase of Investments-337.17-138.29-256.12-94.90-137.300.000.00-62.37-1.45
Sale Or Maturity of Investments135.15179.00349.00117.9653.000.0036.8125.606.54
Other Uses-5.00-5.000.000.000.000.000.000.000.00
Other Sources0.000.00280.030.000.001.3221.040.000.00
Cash from Investing Activities202.2927.41363.1720.24-88.13-11.9539.98-39.304.72
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.941.05-38.42-4.59225.351.4922.002.1360.88
Repurchase of Common Pref Stock0.000.00-40.49-5.41-0.560.000.000.000.00
Sale of Common Pref Stock0.941.052.070.83225.921.4922.002.1360.88
Proceedsfrom Stock Options0.340.520.920.00225.001.2821.551.0760.67
Issuance or Reduction of Debt, Net0.000.00-63.74-2.0818.1616.340.003.170.00
Change in Long Term Debt0.000.00-63.74-2.0825.0016.340.003.170.00
Issuance of Long Term Debt0.000.000.000.0025.0016.840.0055.000.00
Reduction of Long Term Debt0.000.00-63.74-2.080.00-0.500.00-51.830.00
Net Financing Active Other Cash Flow-1.10-0.48-0.46-0.14-12.76-1.87-1.14-2.52-0.36
Other Financing Activities Uses-1.10-0.48-0.46-0.14-12.76-1.87-1.14-2.52-0.36
Cash from Financing Activities-0.160.57-102.62-6.81230.7615.9620.862.7960.52
Exchange Rate Effect-0.320.84-0.790.03-0.40-0.020.390.060.17
Net Change in Cash137.56-45.52116.32-29.8252.86-40.0745.80-71.6737.34
Free Cash Flow-65.65-82.65-151.81-46.12-93.19-57.33-28.13-37.74-28.43
Preferred Dividends (Cash Flow)-0.00-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments461.11476.72455.18187.57194.90237.09
Short Term Receivables12.9815.7541.6413.4313.5414.61
Inventories17.6217.1018.5919.9825.4224.17
Other Current Assets5.597.306.05233.28238.58230.17
Total Current Assets497.30516.87521.45454.26472.44506.04
Net Property, Plant & Equipment36.3239.5542.6546.0144.1947.25
Total Investments and Advances100.3269.3773.4528.1322.072.59
Deferred Tax Assets0.270.260.2738.63--
Other Assets1.121.171.290.720.931.09
Total Assets635.33627.22639.11567.75539.64556.97
Short Term Debt Incl. Current Port. of LT Debt5.695.625.545.495.115.09
Accounts Payable3.459.558.015.416.627.33
Income Tax Payable4.263.032.98---
Other Current Liabilities37.6238.6025.6797.4196.2385.60
Total Current Liabilities51.0256.8042.20108.31107.9798.02
Long Term Debt21.1422.4723.9525.3422.2823.52
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.820.820.820.811.141.08
Other Liabilities6.597.1611.019.018.609.80
Total Liabilities79.5887.2577.99143.46139.98132.43
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity555.75539.97561.12424.29399.66424.54
Total Shareholders Equity555.75539.97561.12424.29399.66424.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity555.75539.97561.12424.29399.66424.54
Total Liabilities & Stockholders Equity635.33627.22639.11567.75539.64556.97
Book Value Per Share1.411.381.441.101.041.11
Tangible Book Value Per Share1.411.381.441.101.041.11
Full-Time Employees---389--
Price to Book Ratio0.470.570.841.231.171.00
Return on Assets-6.34-9.11-8.22-10.42-17.93-16.55
Return on Equity-7.79-11.18-9.86-13.73-24.63-22.40
Return on Invested Capital-2.86-4.76-7.734.29-8.22-7.47
Quick Ratio9.408.8011.924.014.144.92
Current Ratio9.759.1012.364.194.385.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income13.48-26.76127.0719.28-34.69-33.46
Depreciation1.201.271.411.291.60-0.08
Other Funds (Non Cash)-25.747.21-158.499.1710.4211.79
Funds from Operations-11.06-18.278.3529.74-22.67-21.74
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.907.96-54.95-30.930.471.08
Cash from Operating Activities-6.16-10.31-46.60-1.19-22.20-20.67
Capital Expenditures0.00-0.34-0.57-0.48-0.89-1.89
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses22.4924.99363.220.000.000.00
Purchase or Sale of Investments-17.65-10.24-171.56-2.56-5.7929.39
Purchase of Investments-71.72-51.33-186.56-27.56-59.80-18.61
Sale Or Maturity of Investments54.0641.0915.0025.0054.0048.00
Other Uses0.000.000.00-5.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities4.8314.41191.09-8.04-6.6827.50
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.120.080.750.000.31
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.120.080.750.000.31
Proceedsfrom Stock Options0.000.120.000.210.000.31
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.60-0.26-0.12-0.13-0.11-0.20
Other Financing Activities Uses-0.60-0.26-0.12-0.13-0.11-0.20
Cash from Financing Activities-0.60-0.14-0.040.62-0.110.11
Exchange Rate Effect-0.630.290.12-0.10-0.200.79
Net Change in Cash-2.554.25144.57-8.71-29.207.73
Free Cash Flow-6.16-10.65-47.17-1.67-23.09-22.55

Revenue breakdown

Consumables2024: 40.54M 2025: 36.25M
Instruments2024: 24.89M 2025: 25.41M
Service and Other2024: 25.58M 2025: 23.67M
Americas2024: 37.40M 2025: 30.56M
Asia Pacific2024: 17.96M 2025: 18.78M
EMEA2024: 35.65M 2025: 35.99M
Total Pharmaceutical Preparations revenue2024: 91.01M 2025: 85.33M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.57%2.2M378.7M1.22M
2026-10-150.65%2.4M376.6M1.45M
2026-09-300.67%2.5M376.6M1.79M
2026-09-150.69%2.6M376.6M2.75M
2026-08-310.79%3.0M376.5M3.29M
2026-08-140.64%2.4M376.4M3.39M
2026-07-310.72%2.7M376.3M3.51M
2026-07-150.59%2.2M374.7M3.67M
2026-06-300.91%3.4M374.7M3.72M
2026-06-152.67%10.0M375.3M2.90M
2026-05-293.50%13.1M375.5M2.59M
2026-05-153.44%12.9M375.5M2.53M
2026-04-303.17%11.8M372.5M2.45M
2026-04-152.28%8.5M372.2M2.16M
2026-03-312.76%10.3M373.9M1.89M
2026-03-132.21%8.3M373.9M1.85M
2026-02-272.76%10.2M368.6M1.51M
2026-02-132.85%10.5M368.6M1.66M
2026-01-302.66%9.8M368.6M1.70M
2026-01-152.76%10.2M368.6M1.83M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.950.180.0003380.000.0000.0000.000
call1.000.000.050.052.8001,4070.000.299-0.0050.000
call1.500.000.050.224.5124.000.000.237-0.0080.000
call2.000.001.000.205.39010.000.000.214-0.0090.000
call2.500.000.100.376.0201.000.000.201-0.0090.000
call5.000.000.050.107.3132.000.000.172-0.0100.000
call7.500.000.750.008.7170.000.000.166-0.0120.000
put0.500.001.000.050.00012.000.000.0000.0000.000
put1.000.000.550.507.0936060.00-0.703-0.0060.000
put1.500.351.350.4517.45743.000.00-0.763-0.0080.000
put2.000.851.851.1318.2850.000.00-0.786-0.0090.000
put2.501.352.350.0018.8970.000.00-0.799-0.0090.000
put5.002.006.800.000.0000.000.00-0.825-0.0110.000
put7.504.509.306.500.0000.000.00-0.834-0.0110.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-03425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-30424B3SEC
2026-10-21EFFECTEffectiveness filing by commission orderSEC
2026-10-21424B3SEC
2026-10-21S-4/ASEC
2026-10-09S-4/ASEC
2026-10-05425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-30425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-308-KCurrent report2026-09-30SEC
2026-09-09S-4/ASEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-30SCHEDULE 13G/ASEC
2026-07-29425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-298-K/A2026-07-28SEC
2026-07-28425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-28425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-288-KCurrent report2026-07-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1146.90K100
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12502.57K300
2025-1113.93M1200

Institutional holders

Manager% owned
Casdin Capital, LLC22.74%
VIKING GLOBAL INVESTORS LP15.02%
MAK CAPITAL ONE LLC7.38%
Long Focus Capital Management, LLC6.02%
VANGUARD CAPITAL MANAGEMENT LLC3.14%
BlackRock, Inc.2.11%
Hollow Brook Wealth Management LLC1.32%
Neuberger Berman Group LLC1.27%
Qube Research & Technologies Ltd1.23%
ROYCE & ASSOCIATES LP1.16%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.16%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
ROYCE MICRO-CAP TRUST, INC.0.74%
Fidelity Small Cap Index Fund0.73%
iShares Biotechnology ETF0.68%
VANGUARD RUSSELL 2000 INDEX FUND0.38%
Schwab U.S. Small-Cap ETF0.36%
Fidelity Extended Market Index Fund0.35%
Royce Micro-Cap Fund0.32%
Neuberger Intrinsic Value Fund0.26%

OakChart. LAB. Cached 15 minutes.